PHCEF - PharmaCielo Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
3.0000
+0.1900 (+6.76%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close2.8100
Open2.9000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.7500 - 3.0050
52 Week Range2.7426 - 9.9750
Volume36,100
Avg. Volume45,398
Market Cap288.36M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders
    CNW Group

    PharmaCielo Announces Creso Pharma's Receipt of Australian Court Approval to Convene Meeting of Shareholders

    PharmaCielo's acquisition of Creso Pharma will establish a global medicinal cannabis company, positioned to rapidly develop new markets and grow sales in the expanded footprint served by the combined company. TORONTO, Oct. 2, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), is pleased to announce key developments in respect of its friendly acquisition of Australian Securities Exchange ("ASX") listed Creso Pharma Limited ("Creso Pharma") originally announced on June 6, 2019. Creso Pharma has informed the Company that it has received approval from the Supreme Court of Western Australia (the "Court") to convene meetings of its shareholders and listed optionholders (the "Meetings"), and if thought fit, to approve the Schemes of Arrangement whereby PharmaCielo would acquire all of the issued and outstanding shares and listed options of Creso Pharma (the "Schemes of Arrangement").

  • Baystreet

    Stocks in play: PharmaCielo Ltd.

    Has signed a United States sales agreement with an established multi-state distributor, General Extract ...

  • PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC
    CNW Group

    PharmaCielo Enters the U.S. with $3 Million Q4 Sales Agreement and Completes Introductory Shipments to Multi-state Distributor General Extract LLC

    2019 market introduction revenues projected at minimum $3 million CDN Agreement covers sales and distribution of medicinal CBD isolate in multiple US states commencing in 2019 with allowance for renewal ...

  • PharmaCielo Announces Financial Results for the Second Quarter 2019
    CNW Group

    PharmaCielo Announces Financial Results for the Second Quarter 2019

    Well capitalized with a cash and short-term investments of $33.2 million as of June 30, 2019 Subsequent to quarter completed first commercial export of CBD from Colombia to Europe Have cleared all regulatory ...

  • PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe
    CNW Group

    PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe

    TORONTO and CHAM, Switzerland, Aug. 19, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., confirmed today it successfully completed the first commercial export of CBD isolate to Europe. The inaugural shipment of the high quality CBD isolate, a key ingredient in various cannabis derived therapeutic, nutraceutical, topicals and lifestyle products, was delivered to the Swiss headquarters of Creso Pharma, a global pharmaceutical with expertise in cannabis- and hemp-derived products for human and veterinarian use.

  • PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler
    CNW Group

    PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler

    TORONTO and MONTEVIDEO, Uruguay, Aug. 13, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced it has signed a sales agreement with Uruguay-based Laboratorios Adler ("Adler"). According to the agreement, PharmaCielo will provide Adler with bulk CBD extracts, bulk and bottled CBD oils and veterinary products that will be sold by Adler in Uruguay, Paraguay, Bolivia and Southern Brazil.

  • PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative
    CNW Group

    PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative

    TORONTO and RIONEGRO, Colombia, Aug. 8, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced it has joined the TruTrace Technologies, Inc. ("TruTrace") (CSE:TTT, OTCQB:TTTSF) and Shoppers Drug Mart initiated medical cannabis pilot verification program ("Pilot Program").

  • PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors
    CNW Group

    PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors

    New board consists of diversified experts with domestic and international business, academia, agriculture, trade and healthcare expertise Half of new board members are businesswomen, reflecting the overall ...

  • PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts
    CNW Group

    PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts

    TORONTO and RIONEGRO, Colombia, Aug. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is ramping up its oil processing capabilities in the Company's Rionegro, Colombia facility following the recent acquisition and installation of additional high-performance, high-volume extractors, combined with proprietary extraction techniques.

  • PharmaCielo Completes Acquisition of Ubiquo Telemedicina
    CNW Group

    PharmaCielo Completes Acquisition of Ubiquo Telemedicina

    TORONTO, July 26, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has completed the acquisition of all of the shares (the "Acquisition") of Ubiquo Telemedicina S.A.S. ("Ubiquo Telemedicina"), previously announced on April 20, 2018.

  • PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate
    CNW Group

    PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

    Completion of commercial export permit process clears the way for PharmaCielo to initiate shipment of its medicinal-grade CBD extracts to wholesale distributors and product manufacturers CBD isolate to ...

  • PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer
    CNW Group

    PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer

    RIONEGRO, Colombia, July 22, 2019 /CNW/ - PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Colombia" or the "Company"), the premier cultivator and producer of medicinal-grade cannabis oils and extracts in Colombia and subsidiary of Canadian firm PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF), is pleased to announce the appointment of Andres Felipe Botero as Chief Operations Officer (COO).

  • PharmaCielo Announces Trading on the OTC Market
    CNW Group

    PharmaCielo Announces Trading on the OTC Market

    TORONTO and RIONEGRO, Colombia, June 21, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO) (OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce that it is trading on the OTC Markets under the symbol "PHCEF". "With our recently announced acquisition agreement with Creso Pharma (ASX:CPH.AX - News) there is increased attention and interest in our stock. Trading on the OTC will increase access for U.S. and international investors, providing greater liquidity and better access to capital. As we move forward building a global medicinal cannabis company, we will work to provide easy access and liquidity for investors in all jurisdictions," said David Attard, Chief Executive Officer of PharmaCielo Ltd.

  • PharmaCielo to Acquire International Cannabis Company Creso Pharma for A$122 Million
    CNW Group

    PharmaCielo to Acquire International Cannabis Company Creso Pharma for A$122 Million

    TORONTO, June 6, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has entered into a scheme implementation agreement (the "Implementation Agreement") pursuant to which PharmaCielo has agreed to acquire all of the issued and outstanding shares and listed options of Creso Pharma Ltd. ("Creso Pharma") (ASX:CPH.AX - News), for an aggregate purchase price of approximately A$122 million (the "Acquisition").  Creso Pharma is a global medicinal cannabis company that specializes in research, development and production of therapeutic, nutraceutical and animal health products. PharmaCielo will pay A$0.63 per Creso Pharma share, representing a premium of 50% over the closing trading price of the Creso Pharma shares on May 31, 2019.

  • PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor
    CNW Group

    PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor

    TORONTO, May 29, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it has enlisted former U.S. congressman and long-time medical cannabis advocate Dana Rohrabacher as a special advisor to the Company.

  • CNW Group

    Latin American Countries Offer Unique Benefits to Cannabis Cultivators

    Predominantly, most countries which have adopted cannabis legislation have legalized the plant specifically for medical purposes. Countries such as Argentina, Chile, Colombia, and Brazil have all legalized medical cannabis, while some have also decriminalized cannabis, allowing for moderate personal consumption. In combination, all of these factors are further accelerating the Latin American cannabis industry by inviting new business opportunities.

  • PharmaCielo Announces its Financial Results for the Fourth Quarter and Fiscal Year 2018
    CNW Group

    PharmaCielo Announces its Financial Results for the Fourth Quarter and Fiscal Year 2018

    Oil processing facility is on track for commercial operation and GMP certification during Q3-2019, enabling large-scale production and sale of refined cannabis oil. Currently, 10 hectares are under active cultivation, expanding to 20 hectares (~2.15 million square feet) by year-end 2019, backed by 20 proprietary registered strains and 186 strains in the Company's germplasm bank. PharmaCielo's common shares began trading on the TSX Venture Exchange ("TSXV" or "TSX Venture") under the ticker PCLO on January 18, 2019.

  • CNW Group

    Tourists Find New and Destination-Worthy Attractions in Cannabis

    Additionally, a survey conducted by Colorado Tourism reported that 12 million, or approximately 15%, of those travelers participated in marijuana-related activities. Around the world, even though the cannabis industry remains in its infancy stage, more and more countries continue to legalize the plant. Thusly, the consumer base is projected to grow, propelling the overall market even further, as according to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023.

  • CNW Group

    PharmaCielo Doubles Its Portfolio of Proprietary Cannabis Strains Approved for Colombia's Cultivar Registration

    TORONTO and RIONEGRO, COLOMBIA, March 29, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that its Colombian subsidiary has received from the national cultivar registry approval for the listing of a further 10 strains, each of which has a prominent tetrahydrocannabinol (THC) profile. The additional registration of the new strains to the national cultivar registry, including a unique 1:1 THC to CBD ratio strain, doubles the number of approved strains PharmaCielo holds in the registry, making it the largest holder of approved strains in Colombia.

  • CNW Group

    Cannabis Companies Continue Their Growth With New Institutional Backing

    NEW YORK, March 5, 2019 /CNW/ -- The cannabis industry has recently been finding backers in major global investment banking firms such as Piper Jaffray, RBC Capital Markets, and Cowen. Piper Jaffray analyst Michael Lavery noted that there are more than 25 countries that have legalized marijuana of some form. According to data compiled by MarketsandMarkets, the global cannabis market is projected to grow from USD 10.3 Billion in 2018 to USD 39.4 Billion by 2023.

  • Baystreet

    The Top Cannabis Stocks with a Powerful Colombian Market Catalyst

    With favorable cannabis-growing conditions, Colombia is quickly emerging as an industry hot spot. In ...

  • CNW Group

    Cannabis Companies Pursuing Growth Set Sights on Latina America

    NEW YORK, Feb. 28, 2019 /CNW/ --The Latin America region has become highly sought after for cannabis businesses due to the opportunities it represents. Around the globe, many cannabis businesses have moved to establish operations in LATAM because of the area's low cultivation costs and fertile farming lands, as countries including Peru, Chile, Argentina, and Colombia have all passed favourable medical cannabis laws. Meanwhile, Uruguay has entirely legalized cannabis for both recreational and medical use.

  • CNW Group

    Countries Following in Canada's Footsteps on Cannabis Legalization

    NEW YORK, Feb. 25, 2019 /CNW/ -- Following Canada's legalization of cannabis, the North American cannabis industry is positioned to account for the majority of the global marketplace. Canada legalized recreational cannabis nationwide in October, making it the first G-7 country to do so. Now, Mexico's President-elect party is moving to legalize cannabis as well.

  • CNW Group

    Continued Market Expansion is Driving Cannabis Companies to New Regions

    NEW YORK, Feb. 19, 2019 /CNW/ -- The expansion of the cannabis industry has led companies involved in the marketplace to expand internationally as larger players are extending their operations into other regions such as Europe and Latin America. According to Verified Market Intelligence, the global marijuana market was valued at USD 42.20 Billion in 2017 and is expected to reach USD 466.81 Billion by 2025. The market is primarily being accelerated by the growing adoption of medical cannabis for the treatment of chronic diseases.

  • CNW Group

    Cannabis Businesses Eye Latin America in Effort to Reduce Costs

    NEW YORK, Feb. 14, 2019 The cannabis industry is an attractive investment opportunity for entrepreneurs, however, entering into the market poses a challenge for many. In order to mitigate their losses, many began to establish operations in Latin America, specifically in countries such as Argentina, Brazil, Chile, Colombia, and Peru. According to data compiled by BDS Analytics in partnership with Arcview Research, the South American legal cannabis spending is expected to grow from USD 125 Million in 2018 to USD 776 Million by 2026.